A chronic, autoimmune inflammatory liver disorder characterized by narrowing and scarring of the lumen of the bile ducts. It is often seen in patients with ulcerative colitis. Signs and symptoms inclu...
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on sclerosing cholangitis is limited due to its rarity and the complexity of its clinical features, which can overlap with other liver diseases. Additionally, the genetic basis of the condition is still being explored, and systematic clinical studies have been sparse. This can lead to feelings of isolation for patients, but ongoing research may provide more clarity in the future.
To navigate sclerosing cholangitis, consider seeking a hepatologist with expertise in autoimmune liver diseases. They can provide specialized care and management strategies. Additionally, explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for information and support. While no patient organizations are currently identified, staying informed about clinical trials and research opportunities may also be beneficial. Genetic counseling may be useful given the involvement of specific genes.
There are currently 51 active clinical trials investigating various aspects of sclerosing cholangitis. Notable orphan drugs in development include (S)-3-((S)-2-(2-((2,6-difluorophenyl)amino)-2-oxoacetamido)propanamido-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid, 2-[3-(2-chloro-4-{[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy}phenyl)-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid¿2-amino-2-(hydroxymethyl)propane-1,3-diol, 5-cholesten-3ß, 25-diol 3-sulfate sodium salt (25HC3S), and Beta-Lapachone. For more information on ongoing trials, visit ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=sclerosing%20cholangitis.
Actionable guidance for navigating care for sclerosing cholangitis
To navigate sclerosing cholangitis, consider seeking a hepatologist with expertise in autoimmune liver diseases. They can provide specialized care and management strategies. Additionally, explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for information and support. While no patient organizations are currently identified, staying informed about clinical trials and research opportunities may also be beneficial. Genetic counseling may be useful given the involvement of specific genes.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 4 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning sclerosing cholangitis
Updated Feb 20, 2026
Recent research explores the use of oral vancomycin for treating primary sclerosing cholangitis and its associated inflammatory bowel disease. This study may pave the way for new therapeutic approaches in managing these conditions.